Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | -90.00% |
|
0.00% | -99.67% |
Valuation
Fiscal Period: December | 2020 | 2021 |
---|---|---|
Capitalization 1 | 12.17 | 13.76 |
Enterprise Value (EV) 1 | 10.8 | 8.027 |
P/E ratio | -1.4 x | -5.64 x |
Yield | - | - |
Capitalization / Revenue | 6.1 x | 0.81 x |
EV / Revenue | 5.41 x | 0.47 x |
EV / EBITDA | -2.28 x | -35 x |
EV / FCF | -8,406,247 x | 3,439,916 x |
FCF Yield | -0% | 0% |
Price to Book | 1.94 x | 1.95 x |
Nbr of stocks (in thousands) | 30,259 | 36,496 |
Reference price 2 | 0.4022 | 0.3770 |
Announcement Date | 30/04/21 | 02/05/22 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|
Net sales 1 | 0.26 | 1.449 | 1.994 | 17.06 |
EBITDA 1 | -1.715 | -3.381 | -4.726 | -0.2291 |
EBIT 1 | -1.829 | -3.553 | -5.042 | -1.082 |
Operating Margin | -703.46% | -245.2% | -252.85% | -6.35% |
Earnings before Tax (EBT) 1 | -1.859 | -3.797 | -4.787 | -2.247 |
Net income 1 | -1.859 | -3.797 | -4.659 | -2.314 |
Net margin | -715% | -262.04% | -233.61% | -13.57% |
EPS 2 | -0.0520 | -0.0725 | -0.2868 | -0.0669 |
Free Cash Flow | - | -1.976 | -1.285 | 2.333 |
FCF margin | - | -136.4% | -64.41% | 13.68% |
FCF Conversion (EBITDA) | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - |
Dividend per Share | - | - | - | - |
Announcement Date | 14/05/19 | 03/06/20 | 30/04/21 | 02/05/22 |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2022 Q3 |
---|---|
Net sales | - |
EBITDA | - |
EBIT | - |
Operating Margin | - |
Earnings before Tax (EBT) | - |
Net income 1 | -1.266 |
Net margin | - |
EPS | - |
Dividend per Share | - |
Announcement Date | 10/11/22 |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|
Net Debt 1 | - | - | - | - |
Net Cash position 1 | 3.74 | 1.37 | 1.37 | 5.73 |
Leverage (Debt/EBITDA) | - | - | - | - |
Free Cash Flow | - | -1.98 | -1.28 | 2.33 |
ROE (net income / shareholders' equity) | - | -89.7% | -95.2% | -34.7% |
ROA (Net income/ Total Assets) | - | -45.3% | -49.4% | -7.1% |
Assets 1 | - | 8.378 | 9.432 | 32.59 |
Book Value Per Share 2 | 0.0100 | 0.0100 | 0.2100 | 0.1900 |
Cash Flow per Share 2 | 0.0100 | 0 | 0.0600 | 0.1700 |
Capex 1 | 0.18 | 0.53 | 0.21 | 0.24 |
Capex / Sales | 69.62% | 36.23% | 10.58% | 1.42% |
Announcement Date | 14/05/19 | 03/06/20 | 30/04/21 | 02/05/22 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-99.67% | 36 | |
+26.93% | 5.55B | |
-33.55% | 3.52B | |
-3.74% | 3.03B | |
-26.09% | 2.59B | |
-10.93% | 2.28B | |
+41.50% | 1.88B | |
+41.84% | 1.46B | |
-12.94% | 1.43B | |
+47.62% | 1.42B |
- Stock Market
- Equities
- GDBYF Stock
- Financials Goodbody Health Limited